Disagreement Between Patient and Physician Global Assessment Over Time in Psoriatic Arthritis: Insight Into Treatment Priorities
File version
Author(s)
Coates, L
Nash, P
Deodhar, A
Nantel, F
Rampakakis, E
Bessette, L
Marrache, M
Lavie, F
Shawi, M
Tillett, W
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Milan, Italy
License
Abstract
Background The PsA core domain set developed by the Outcome Measures in Rheumatology working group includes musculoskeletal disease, fatigue, physical function, and structural damage, of which arthritis activity, pain, and fatigue were identified as essential by both patients (Pts) and physicians (Phs).[1-2] Assessing agreement between Pt and Ph global assessments (GA) may provide valuable insight into differential importance of specific PsA manifestations to Pts vs Phs. Although previous studies have assessed Pt/Ph disagreement, they have not evaluated potential variation over time.[3]
Objectives To assess agreement of PtGA and PhGA through week (W) 24 and identify factors driving disagreement between PtGA and PhGA using pooled data (N=1120) from the phase 3 DISCOVER (D)-1 & -2 studies of the fully human IL-23p19 subunit inhibitor (i), guselkumab (GUS).
Methods Pts with active PsA despite standard therapies (D1: ≥3 swollen/tender joint counts [SJC/TJC], CRP ≥0.3 mg/dL, ~30% with prior TNFi; D2: ≥5 SJC/TJC, CRP ≥0.6 mg/dL, biologic-naïve) were randomized 1:1:1 to GUS 100 mg every 4 weeks (Q4W); GUS 100 mg at W0, W4, Q8W; or placebo. Pt/Ph agreement was defined as a difference of -15<PhGA-PtGA<15. Determinants of PhGA exceeding PtGA by ≥15 (PhGA>PtGA) and PtGA exceeding PhGA by ≥15 (PtGA>PhGA) among pts with PtGA/PhGA disagreement were assessed with the same logistic regression model considering pt demographics, disease characteristics, and pt-reported outcomes (PROs). The effect of GUS on disease parameters identified as determinants of PtGA vs. PhGA disagreement was assessed with repeated measures mixed models adjusting for treatment group, baseline (BL) levels, prior TNFi use, and BL DMARD use.
Results At BL, mean (SD) SJC=11.5 (7.4), TJC=20.6 (13.3), FACIT-Fatigue score=29.9 (10.0), PtGA=66.9 (19.9), and PhGA=64.8 (15.9) were consistent with moderate to high disease activity. Agreement between PtGA and PhGA was seen in most instances (61.2%); 23.2% of cases were characterized by PtGA>PhGA and 15.7% by PhGA>PtGA. The proportion of pts with PtGA>PhGA increased to 39.1% at W24, while that with PhGA>PtGA decreased to 11.2%. The main determinant of PtGA>PhGA was higher Pt Pain (all time points); additional factors included worse physical health-related quality of life at BL and worse fatigue at W24 (Table 1). Conversely, Phs emphasized objective disease measures, namely higher SJC (all time points) and TJC (W8 to W24), and elevated CRP (BL to W16). GUS treatment was associated with prompt and sustained significant improvements in all identified determinants, including those driving PtGA>PhGA (Figure 1).
Conclusion PtGA and PhGA were aligned in most encounters. PtGA>PhGA disagreement was driven by pain, fatigue, and physical health being weighed more by Pts than Phs. These findings have important implications in shared decision making and highlight the need to prioritize treatments addressing the full spectrum of PsA symptoms, including PROs.
References [1]Leung YY, et al. J Rheum. 2020 (Suppl);96:46
[2]Mease PJ, et al. Ann Rheum Dis. 2022;81:879
[3]Desthieux C, et al. Arthritis Care Res. 2017;69:1606
Journal Title
Annals of the Rheumatic Diseases
Conference Title
EULAR 2023 European Congress of Rheumatology, 31 May - 3 June. Milan, Italy
Book Title
Edition
Volume
82
Issue
Suppl 1
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject
Clinical sciences
Immunology
Science & Technology
Life Sciences & Biomedicine
Rheumatology
Persistent link to this record
Citation
Rahman, P; Coates, L; Nash, P; Deodhar, A; Nantel, F; Rampakakis, E; Bessette, L; Marrache, M; Lavie, F; Shawi, M; Tillett, W, Disagreement Between Patient and Physician Global Assessment Over Time in Psoriatic Arthritis: Insight Into Treatment Priorities, Annals of the Rheumatic Diseases, 2023, 82 (Suppl 1), pp. 345-346